Sarcoma
SJR0.560
US
USJournal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | — | — | 0.560 | Q2 | 65.2% | |
| 2024 | — | — | 0.666 | Q2 | 71.9% | |
| 2023 | — | — | 0.545 | Q2 | 67.7% | |
| 2022 | — | — | 0.549 | Q2 | 69.2% | |
| 2021 | — | — | 0.715 | Q2 | 78.1% | |
| 2020 | — | — | 0.781 | Q2 | 79.1% | |
| 2019 | — | — | 0.651 | Q2 | 74.9% | |
| 2018 | — | — | 0.912 | Q1 | 82.1% | |
Impact history
Annual SJR and Impact Factor trend.
SJR
Journal record
eISSN
1369-1643
ISSN
1357-714X
country
UScoverage
1997-2024